SCHEMBL24248129

SCHEMBL24248129

CCCNC(=O)c1sc2nc(CC)cnc2c1NC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP28 Q96RU2 6/20 0.44
USP25 Q9UHP3 4/20 0.44
CHRM4 P08173 2/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 2/20 0.34
POLB P06746 2/20 0.34
TP53 P04637 2/20 0.33
IKBKB O14920 2/20 0.32
HPGD P15428 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
CHUK O15111 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ESR1 P03372 1/20 0.32
JMJD7 P0C870 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
STAT3 P40763 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25800838 0.86 CHRM4 (0.39) USP28USP25CHRM4POLBTP53
SCHEMBL22645075 0.76 USP25 (0.81) USP28USP25
SCHEMBL24595753 0.74 USP28 (0.49) USP28USP25TP53
SCHEMBL24248137 0.70 KDM4E (0.40) USP28USP25CHRM4KDM4EALDH1A1
SCHEMBL24248138 0.69 SMN1; SMN2 (0.41) CHRM4KDM4EALDH1A1POLBTP53
SCHEMBL25800841 0.69 NPC1 (0.40) USP28USP25CHRM4KDM4EALDH1A1
SCHEMBL21457816 0.68 USP28 (0.47) USP28USP25KDM4EALDH1A1IKBKB
SCHEMBL22645007 0.66 KDM4E (0.47) USP28USP25CHRM4KDM4EALDH1A1
SCHEMBL24248117 0.65 IKBKB (0.49) CHRM4KDM4EALDH1A1POLBTP53
SCHEMBL17920678 0.65 CHRM4 (0.63) CHRM4KDM4EALDH1A1POLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3954694-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITORS, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Chaser Therapeutics, Inc. (CN) 2022-02-16 EP disclosed